Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for OCD Fears
NCT02790710Phase 4Withdrawn
- Sponsor
- New York State Psychiatric Institute
- Start
- Jun 2016
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obsessive compulsive disorder (OCD) comparing Propanolol with Placebo capsule (2 arms). Primary endpoint: Yale Brown Obsessive-Compulsive Scale at 2 weeks. Planned start Jun 2016; status: withdrawn.
02
Drugs
propranolol
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT02790710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790710.